Literature DB >> 9706826

Prevention of congestive heart failure by early, prehospital thrombolysis in acute myocardial infarction: a long-term follow-up study.

A T Weiss1, I Leitersdorf, M S Gotsman, D Zahger, D Sapoznikov, Y Rozenman, D Gilon.   

Abstract

The long term impact of pre-hospital thrombolysis in acute myocardial infarction on the subsequent development of heart failure symptoms was investigated in 362 consecutive patients. The pre hospital strategy, used in 61 patients, allowed for very early administration of streptokinase, within 1.2+/-0.6 (mean+/-S.D.) hours from pain onset. In contrast, 294 patients treated in hospital received lytic treatment within 2.0+/-0.9 hours. The pre hospital group showed faster reperfusion, as measured by the time to peak creatine kinase and to ST segment recovery, but only a slightly better ventricular function, as compared to hospital treated patients. Heart failure symptoms were significantly reduced in the pre hospital group during hospitalization and at long term follow up: there were less dyspnea, fatigue, orthopnea, nocturnal dyspnea, nocturia, peripheral edema and episodes of pulmonary edema. Angina was reduced as well. We conclude that the initial benefit of prehospital thrombolysis translates into long term reduction of heart failure symptoms, thus improving quality of life.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9706826     DOI: 10.1016/s0167-5273(98)00062-x

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  2 in total

1.  The chronic kidney disease model: a general purpose model of disease progression and treatment.

Authors:  Lori A Orlando; Eric J Belasco; Uptal D Patel; David B Matchar
Journal:  BMC Med Inform Decis Mak       Date:  2011-06-16       Impact factor: 2.796

2.  Prehospital thrombolysis--calculated health benefit for catchment population of one hospital.

Authors:  Mark Kroese; David Kanka; Peter Weissberg; Barbara Arch; John Scott
Journal:  J R Soc Med       Date:  2004-05       Impact factor: 18.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.